Company news
Imunon, Inc. news in 2024
Imunon, Inc.'s news releases, calls and decks from 2024, newest first.
IMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
December 18, 2024
IMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
December 9, 2024
IMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
November 24, 2024
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates
November 6, 2024
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
November 6, 2024
IMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
October 30, 2024
IMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
October 29, 2024
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
October 6, 2024
IMUNON’s Ovarian Cancer R&D Day to Feature Presentations from IMNN-001 Clinical Study Investigators, Immunology and Biostatistics Experts, and Executive Management
September 8, 2024
IMUNON to Host R&D Day on September 18th
August 27, 2024
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
August 13, 2024
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
August 6, 2024
IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
July 30, 2024
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
July 29, 2024
IMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
July 28, 2024
IMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
June 23, 2024
First Participants Vaccinated in IMUNON’s IMNN-101 Phase 1 Clinical Trial
June 4, 2024
Abstract on Phase 2 Study with IMUNON’s IMNN-001 Plus Bevacizumab Accepted for Presentation at the American Society of Clinical Oncology Annual Meeting
May 14, 2024
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update
May 12, 2024
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
May 12, 2024
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO
May 7, 2024
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
May 5, 2024
IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
April 17, 2024
IMUNON Reports Compliance with Nasdaq Listing Requirements
April 10, 2024
IMUNON Reports 2023 Financial Results and Provides Business Update
March 27, 2024
IMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
March 24, 2024
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
March 20, 2024
IMUNON Files IND Application to Begin Human Testing of IMNN-101
March 12, 2024
IMUNON Announces Leadership Change
March 11, 2024
Independent Lab Confirms Immunogenicity and Protection with IMUNON’s IMNN-101 in a Live Virus Challenge Against SARS-CoV-2 Variant XBB.1.5
February 28, 2024
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
February 26, 2024
IMNN-101 Preclinical Data in SARS CoV-2 Published in Peer-Reviewed Journal Vaccine
February 21, 2024
Calls in 2024
Decks in 2024
- Technical Presentation (July 2024)
Technical · 20 slides · Jul 30, 2024